Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis

Pancreatitis Clinical Trial

Official title:

Randomised Controlled Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02630433
• Other study ID #: Gallstenspancreatitistudien
• Status: Completed
• Phase: N/A
• First received: December 6, 2015
• Last updated: November 12, 2017
• Start date: August 2009
• Est. completion date: November 12, 2017

Study information

• Verified date: November 2017
• Source: Karolinska Institutet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There are controversies optimal timing for cholecystectomy in patients with mild biliary pancreatitis. The safety of cholecystectomy performed during an episode of pancreatitis has been questioned. The aim of the present randomized controlled trial is to compare the outcome in terms of recurrent pancreatitis and gallstone-related events between index cholecystectomy, performed during the first admission for acute pancreatitis, and scheduled cholecystectomy, performed 4-6 weeks after discharge.

Description:

Background:

There is still considerable debate regarding the optimal timing of cholecystectomy in mild biliary pancreatitis. It is widely accepted to wait until the patient's clinical condition allows performing cholecystectomy in severe biliary pancreatitis with systemic or local complications. On the other hand, the recommendations are not very clear when it comes to patients with mild biliary pancreatitis. The British Society of Gastroenterology and American Gastroenterological Association guidelines recommendation is to perform cholecystectomy within 2-to 4- week interval after the initial episode. However, the safety of cholecystectomy performed during an episode of pancreatitis is also controversial.

In a systematic review the overall readmission rate was 18% after index cholecystectomy, 8% for recurrent biliary pancreatitis, 3 % for acute cholecystitis and 7 % for biliary colic.

Methods The study is performed as a Randomised controlled trials with two parallel arms and a ratio of 1:1. Patients admitted with acute pancreatitis are checked for eligibility criteria for the study. Mild pancreatitis is defined as pancreatitis without local complications such as necrosis or organ failure. Patients who are eligible obtained oral and written information about the study and invited to be included. Patients who accept participation sign a consent form and are included. The included patients are randomized into index cholecystectomy (IC) or scheduled cholecystectomy (SC).

Randomization is done with a sealed envelope system. The allocation sequence is created by an online random generator. There is no blocking. After randomization, the patient as well as the responsible are immediately informed about the allocation.

The IC and SC are protocolled to be performed within 24-48 hours from randomization, and after 6 weeks from discharge respectively. Daily blood samples, pain and well-being scores are obtained during index admission until discharge, at 1-month follow-up for SC group and at the scheduled cholecystectomy. Quality of life is assessed with SF-36 prior to randomization and 4 weeks after inclusion. Pain is measured with the McGill Pain Questionnaire before randomization and daily until discharge of two days after inclusion.

Sample size estimation If IC reduces the risk of gallstone- or treatment-related adverse events from 40% to 10%, a total sample of 32 patients in each group is required in order to reach a chance of 80% of detecting a significant difference at the p<0.05 level. In order to compensate of drop-outs, a total sample of 70 is stipulated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: November 12, 2017
• Est. primary completion date: November 12, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• S-Amylase >3 microkat/L

• One or more gallstones with diameter < 2 cm

• S-CRP < 150 mg/L the first 24 hours

Exclusion Criteria:

• Multiple organ failure

• Solitary gallstone with diameter >2 cm

• Concurrent cholangitis

• Hospital stay exceeding 72 hours before screening for inclusion

Related Conditions & MeSH terms

• Pancreatitis

Intervention

Procedure:
• Index cholecystectomy
Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
• Scheduled cholecystectomy
Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.

Locations

Country	Name	City	State
Sweden	Karolinska University Hospital, Center for Digestive Diseases	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrent acute pancreatitis	Relapse of acute pancreatitis in the scheduled cholecystectomy arm	6 weeks
Secondary	Complications related to the cholecystectomy	Complications according to the Clavien-Dindo classification	30 days
Secondary	Markers of inflammatory activity	Inflammatory response measured with CRP and interleukins	3 days
Secondary	Health-related quality of life measured with SF-36	Health-related quality of life measured with SF-36 the day of inclusion and 6 weeks after inclusion	6 weeks
Secondary	Cost-effectiveness	Costs from hospital stay, the surgical procedure and sick leave.	6 weeks